Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Top Cited Papers
- 1 September 2014
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 4 (9), 998-1013
- https://doi.org/10.1158/2159-8290.cd-14-0001
Abstract
Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. Cancer Discov; 4(9); 998–1013. ©2014 AACR.Keywords
Other Versions
This publication has 77 references indexed in Scilit:
- Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic ProfilingScience Translational Medicine, 2012
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal CarcinomasClinical Cancer Research, 2012
- Patient-derived tumour xenografts as models for oncology drug developmentNature Reviews Clinical Oncology, 2012
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature, 2012
- A Model for Personalized in Vivo Analysis of Human Immune ResponsivenessScience Translational Medicine, 2012
- Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug TherapyCell Stem Cell, 2011
- Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive BiomarkersClinical Cancer Research, 2008
- Phenotypic instability of Saos-2 cells in long-term cultureBiochemical and Biophysical Research Communications, 2005
- Development of Three Human Small Cell Lung Cancer Models in Nude MicePublished by Springer Science and Business Media LLC ,1985
- Current NCI Preclinical Antitumor Screening in Vivo: Results of Tumor Panel Screening, 1976–1982, and Future DirectionsPublished by Elsevier BV ,1984